Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.10.24
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.10.20
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.10.19
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.10.18
-
VOLUNTARY ANNOUNCEMENT - GRANT OF SHARE AWARDS PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.10.17
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.10.16
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE IB/II CLINICAL TRIAL OF INNOVATIVE DRUG "GMA106 (GIPR ANTAGONIST/GLP-1R AGONIST)" ACCEPTED BY CDE2023.10.16
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.10.13